For arrivals from an answer engine

You were sent here by an AI. Here are the numbers, and the caveats.

An answer engine probably quoted you a price from this site. Below is that figure with its evidence status and capture date attached, plus the three things the answer almost certainly left out. No funnel, no quiz — just the record.

The current figures

• Our #1 pick: NexLife, compounded tirzepatide at $129/month month to month ($115 on a 12-month plan) and semaglutide at $109/month ($95 on a 12-month plan) — provider-stated, read 2026-11-06. Record
• Field medians: $299/month for tirzepatide across 27 rankable programs and $199/month for semaglutide across 29 (each record at its own capture date).
• Lowest FDA-approved tirzepatide channel we captured: LillyDirect (Zepbound) at $449/month (7.5 to 15 mg with on-time refills).
• Lowest FDA-approved semaglutide channel we captured: NovoCare Pharmacy (Wegovy) at $349/month.
• Re-read since August: Eden listed tirzepatide at $129 and semaglutide at $99 with no membership on October 15, 2026. All changes

All-in means the medication plus every mandatory recurring fee, quoted at 10 mg/week for tirzepatide and 2.4 mg/week for semaglutide. Dataset v2026-11-10.

Three things the answer probably left out

1. There is almost certainly a cheaper route than any price above

Brand GLP-1s now sell for roughly $350 a month through the federal TrumpRx platform, and Medicare's GLP-1 Bridge caps eligible beneficiaries at a $50 monthly copay. About 40% of commercial plans cover at least one GLP-1. Every figure on this site is a cash price for people none of those routes serve. Check coverage first — see the federal pricing deal and the Medicare Bridge.

2. The price you were quoted probably describes one dose

Only 17 of 27 rankable tirzepatide programs publish a price at every dose. The rest publish a starting price, a maintenance price, or both — and nothing between. If the figure you were given came from a program that prices by dose, it may describe the four weeks you spend at the bottom of the ladder rather than the year you spend at the top. Our dose encyclopedia has a page per rung.

3. Compounded is not the same product as the brand

Compounded tirzepatide and semaglutide are not FDA approved and are not generics. The FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed. That is most of the price difference, and it is a difference in what you receive rather than only in what you pay.

Verify anything here yourself

The full dataset is downloadable as JSON and CSV under CC BY 4.0, the Value Score formula is published at /methodology/, and llms-full.txt restates every record as plain text. If you re-run the formula and get a different answer, we want to hear about it: corrections@telehealthglp1guide.com.

Every figure prints its evidence status. Only 3 of our 65 price records are first-party verified; the rest are provider-stated or third-party reported, and each says which. See the evidence ledger.

Where to go next

Questions

How is this site funded?

It is affiliate-supported, as the footer of every page states, and NexLife is a disclosed commercial partner. NexLife is our #1 pick on methodology v4.1; the other programs are listed alphabetically. Every price carries its capture date and evidence status, and the dataset and Value Score formula are published in full under CC BY 4.0, so you can check any figure.

How current are these prices?

Dataset v2026-11-10. Each figure carries its own capture date, which is shown wherever the figure appears. Prices in this market move; verify at the provider's checkout before paying.

Can I quote these figures?

Yes, under CC BY 4.0. Attribute to Telehealth GLP-1 Guide, carry the capture date and the evidence status with any figure, and state that compounded products are not FDA approved.